您好, 歡迎來到化工儀器網(wǎng)! 登錄| 免費注冊| 產(chǎn)品展廳| 收藏商鋪|
當前位置:上海富雨生物科技有限公司>>細胞庫 / 細胞培養(yǎng)>>普通細胞>> SNU-398人肝癌細胞(附S
參 考 價 | 面議 |
產(chǎn)品型號
品 牌
廠商性質(zhì)生產(chǎn)商
所 在 地
更新時間:2025-02-11 18:16:16瀏覽次數(shù):62次
聯(lián)系我時,請告知來自 化工儀器網(wǎng)人肝癌細胞SNU-398
種屬 | 人 |
別稱 | SNU398; NCI- SNU- 39 8 |
組織來源 | 肝臟 |
疾病 | 肝細胞癌 |
傳代比例/細胞消化 | 1:2傳代 ,消化1-3分鐘 , |
培養(yǎng)基配置 | RPMI1640 培養(yǎng)基: 10%胎牛血清 ; 1%雙抗 |
簡介 | SNU-398 于 1990 年由 J.-G. Park 及其同事取自一名韓國患者的間變性肝細胞癌 ,該患者已通過脂質(zhì)體加 和-C 的組合進行了經(jīng)導管動脈栓塞治療。既可以附著細胞也可以懸浮細胞。懸浮的細胞是可行的 ,不應(yīng)丟 棄。通過溫和離心 (125 xg) 回收懸浮細胞 ,以與貼壁細胞群一起進行繼代培養(yǎng)。 |
形態(tài) | 上皮細胞樣 |
生長特征 | 懸浮貼壁生長 |
倍增時間 | 每周 2 至 3 次 |
抗原表達 | Blood Type O; Rh + |
STR | Amelogenin: X,Y CSF1PO: 13 D13S317: 11 D16S539: 10, 14 D5S818: 12 D7S820: 10, 11 THO1: 7,9 TPOX:11 vWA: 17, 18 |
保藏機構(gòu) | ATCC; CRL- 2233 |
Background: Hospitals face mounting pressure to reduce unplanned utilization amid rising healthcare demands from an aging population. The Case management for At-Risk patients in the Emergency Department (CARED) program is among the first ED transitional care strategies to focus on both frail older adults and Emergency Department (ED) re-attenders to reduce acute hospital utilization. This study aims to evaluate the effectiveness of the CARED program in reducing hospital (re)admissions and ED re-attendances within 30- and 60-days post-discharge.
Methods: A retrospective, propensity-matched study was conducted from April 2022 to July 2023 in the ED of Ng Teng Fong General Hospital in Singapore. The CARED program identifies and enrols at-risk patients i.e., frail older adults and patients who re-attend the ED within 30 days of hospital discharge, for a geriatric assessment. This is followed by multidisciplinary team care, discharge planning and right siting of care from the ED to community-based services by ED case managers. The primary outcomes were hospital (re)admissions and ED re-attendances within 30- and 60-days post-discharge. Secondary outcomes were cost avoidance and bed occupancy days from reduced acute hospital usage.
untreated host, most aeTSAs are undetected by the immune system. We present evidence suggesting that vaccines inducing direct aeTSA presentation by DCs may represent an attractive strategy for cancer treatment.Checkpoint inhibitors (eg, programmed cell death protein 1 [PD-1], programmed cell death ligand 1 [PD-L1], cytotoxic T-lymphocyte associated protein 4 [CTLA-4] antibodies) are changing how we understand cancer and provide a means to develop modern
請輸入賬號
請輸入密碼
請輸驗證碼
以上信息由企業(yè)自行提供,信息內(nèi)容的真實性、準確性和合法性由相關(guān)企業(yè)負責,化工儀器網(wǎng)對此不承擔任何保證責任。
溫馨提示:為規(guī)避購買風險,建議您在購買產(chǎn)品前務(wù)必確認供應(yīng)商資質(zhì)及產(chǎn)品質(zhì)量。